Tucotuzumab celmoleukin

Tucotuzumab celmoleukin
Monoclonal antibody
Type	Whole antibody
Source	Humanized (from mouse)
Target	EpCAM
Clinical data
Other names	EMD 273066
ATC code	none
Identifiers
CAS Number	339986-90-2^Y
ChemSpider	none
UNII	4ON7FF680U
KEGG	D09027^Y
Chemical and physical data
Formula	C₇₈₁₂H₁₂₁₂₄N₂₀₄₄O₂₄₀₈S₆₀
Molar mass	175130.42 g·mol⁻¹
(verify)

Tucotuzumab celmoleukin is an anti-cancer drug. It is a fusion protein of a humanized monoclonal antibody (tucotuzumab) and an interleukin-2 (celmoleukin).^[1]^[2]^[3]

This drug was developed by EMD Pharmaceuticals.

References

^ Statement On A Nonproprietary Name Adopted By The Usan Council - Tucotuzumab Celmoleukin, American Medical Association.
^ Clinical trial number NCT00016237 at ClinicalTrials.gov
^ "Definition of tucotuzumab celmoleukin". National Cancer Institute.

Monoclonal antibodies for tumors

Human	Adecatumumab^§ Amivantamab Ascrinvacumab^§ Balstilimab^† Botensilimab Cixutumumab^§ Conatumumab^§ Cosibelimab Daratumumab Drozitumab^§ Duligotumab^§ Dusigitumab^§ Enfortumab vedotin Enoticumab^§ Figitumumab^§ Flanvotumab^§ Ganitumab^† Glembatumumab vedotin^† Intetumumab^§ Ipilimumab Iratumumab^§ Istiratumab Icrucumab^§ Lexatumumab^§ Linvoseltamab Lucatumumab^§ Mapatumumab^§ Narnatumab^§ Necitumumab Nesvacumab^§ Nivolumab^# (+hyaluronidase, +relatlimab) Ofatumumab Olaratumab^† Panitumumab Patritumab^§ Pritumumab^§ Radretumab^§ Ramucirumab Rilotumumab^† Robatumumab^§ Seribantumab^§ Sugemalimab Tarextumab^§ Tisotumab vedotin Teprotumumab^† Tovetumab^§ Vantictumab^§ Votumumab^§ Zalutumumab^†
Mouse	Abagovomab Altumomab pentetate Anatumomab mafenatox Arcitumomab Bectumomab Blinatumomab Capromab pendetide Detumomab Edrecolomab Ibritumomab tiuxetan Igovomab Lilotomab Minretumomab Mitumomab Nacolomab tafenatox Moxetumomab pasudotox Naptumomab estafenatox Oregovomab Pemtumomab^† Racotumomab Satumomab pendetide Solitomab Taplitumomab paptox Nofetumomab merpentan Pintumomab Tenatumomab Tositumomab
Chimeric	Amatuximab^§ Bavituximab^§ Brentuximab vedotin Carotuximab^† Cetuximab Derlotuximab biotin^§ Dinutuximab Ecromeximab^§ Ensituximab^§ Futuximab^§ Girentuximab^† Indatuximab ravtansine^§ Isatuximab Loncastuximab tesirine Margetuximab Mirvetuximab soravtansine Rituximab^# Siltuximab Ublituximab Zolbetuximab
Humanized	Abituzumab^§ Alemtuzumab Atezolizumab (+hyaluronidase) Axatilimab Belantamab mafodotin Bevacizumab Bivatuzumab mertansine^§ Brontictuzumab^§ Cantuzumab mertansine^§ Cantuzumab ravtansine^§ Cirmtuzumab Citatuzumab bogatox^§ Clivatuzumab tetraxetan Cofetuzumab pelidotin Dacetuzumab^§ Demcizumab^§ Dalotuzumab^§ Datopotamab deruxtecan Denintuzumab mafodotin^§ Elotuzumab Emactuzumab Emibetuzumab^§ Enoblituzumab^§ Epcoritamab Etaracizumab^§ Farletuzumab^§ Ficlatuzumab^§ Flotetuzumab^§ Gemtuzumab ozogamicin Glofitamab Imgatuzumab^§ Inotuzumab ozogamicin Labetuzumab^§ Lifastuzumab vedotin^§ Lintuzumab^§ Lorvotuzumab mertansine^§ Lumretuzumab^§ Matuzumab^§ Milatuzumab^§ Naxitamab Nimotuzumab^† Obinutuzumab Ocaratuzumab^§ Odronextamab Otlertuzumab^§ Onartuzumab^§ Oportuzumab monatox^† Parsatuzumab^§ Pembrolizumab^# (+berahyaluronidase alfa) Penpulimab Pertuzumab Pinatuzumab vedotin^§ Polatuzumab vedotin Rosmantuzumab Rovalpituzumab tesirine^† Sacituzumab govitecan Sibrotuzumab^§ Simtuzumab^§ Sofituzumab vedotin^§ Tacatuzumab tetraxetan^§ Tigatuzumab^§ Trastuzumab^# (+deruxtecan / +emtansine) Tucotuzumab celmoleukin^§ Vandortuzumab vedotin^§ Vanucizumab^§ Veltuzumab^§ Vorsetuzumab mafodotin^§ Zenocutuzumab
Rat/mouse hybrid	Catumaxomab Ertumaxomab^§
Chimeric + humanized	Depatuxizumab mafodotin^† Duvortuxizumab Ontuxizumab^§

^#WHO-EM
^‡Withdrawn from market
Clinical trials:
- ^†Phase III
- ^§Never to phase III

Interleukin receptor modulators

Decoy receptors: Rilonacept (IL-1 Trap)

Antagonists: Pitrakinra

Antibodies: Dupilumab
Pascolizumab

Agonists: Interleukin 5

Antagonists: YM-90709

Antisense oligonucleotides: TPI ASM8

Agonists: Atexakin alfa
Interleukin 6

Agonists: Interleukin 7

See CXCR1 (IL-8Rα) and CXCR2 (IL-8Rβ) here instead.

Agonists: Interleukin 9

Antibodies: Enokizumab

Agonists: Ilodecakin
Interleukin 10 (CSIF)

Agonists: Interleukin 11 (AGIF)
Oprelvekin

Agonists: Edodekin alfa
Interleukin 12

Antibodies: Briakinumab
Ustekinumab

Agonists: ALT-803
Interleukin 15

Agonists: Interleukin 17 (A, B, C, D, E (interleukin 25), F)

Binding proteins: IL18BP

Antibodies: Fletikumab (against IL-20)

Agonists: Denenicokin
Interleukin 21

Antibodies: NNC0114-0005
NNC0114-0006

Agonists: Interleukin 22

Antibodies: Fezakinumab (against IL-22)

Agonists: Interleukin 23 (SGRF)

Agonists: Interleukin 27 (interleukin 30)

Agonists: Interleukin 31

Agonists: Interleukin 33

Agonists: Interleukin 36 (α, β, γ)
Interleukin 38

Antagonists: IL-36RA

Others

JAK	See here instead.
Others	Interleukin 14 (taxilin alpha, HMW-BCGF) Interleukin 16 (signals through CD4) Interleukin 24 (signals through IL-22Rα1/IL-20Rβ heterodimer) Interleukin 26 (signals through IL-20Rα/IL-10Rβ heterodimer) Interleukin 32 Interleukin 34 (signals through M-CSFR/CSF1R) Interleukin 35 Unsorted: Efavaleukin alfa Efineptakin alfa

This monoclonal antibody–related article is a stub. You can help Wikipedia by expanding it.

This antineoplastic or immunomodulatory drug article is a stub. You can help Wikipedia by expanding it.